Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)

Autor: Mariasanta Napolitano, Muriel Giansily-Blaizot, Alberto Dolce, Jean F. Schved, Guenter Auerswald, Jørgen Ingerslev, Jens Bjerre, Carmen Altisent, Pimlak Charoenkwan, Lisa Michaels, Ampaiwan Chuansumrit, Giovanni Di Minno, Ümran Caliskan, Guglielmo Mariani

Publikováno v: Haematologica, Vol 98, Iss 4 (2013)

Because of the very short half-life of factor VII, prophylaxis in factor VII deficiency is considered a difficult endeavor. The clinical efficacy and safety of prophylactic regimens, and indications for their use, were evaluated in factor VII-deficie

Externí odkaz: https://doaj.org/article/2202d40ca6cf499d8622c5ce03237f5b

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)

Autor: Wilfried Seifert, Anna Klukowska, Toshko Lissitchkov, Guenter Auerswald, Tobias Rogosch, Oleksandra Stasyshyn, Evgeny Buevich, Irina Maltceva

Publikováno v: Journal of Blood Medicine

Toshko Lissitchkov,1 Anna Klukowska,2 Evgeny Buevich,3 Irina Maltceva,3 Guenter Auerswald,4 Oleksandra Stasyshyn,5 Wilfried Seifert,6 Tobias Rogosch6 1Specialized Hospital for Active Treatment (SHAT), Sofia, Bulgaria; 2Department of Paediatrics, Haem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c064eec3a6732f8b0e964d4655efb898
https://www.dovepress.com/an-open-label-extension-study-to-assess-the-long-term-efficacy-and-saf-peer-reviewed-article-JBM

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients

Autor: Elena Santagostino, Anne Duffy, Massimo Morfini, Thierry Lambert, Rolf Ljung, Cedric Hermans, Víctor Jiménez-Yuste, Silva Zupančić-Šalek, Gary Benson, Guenter Auerswald, Gerry Dolan

Publikováno v: Biblos-e Archivo. Repositorio Institucional de la UAM
instname
European Journal of Haematology
European Journal of Haematology, Vol. 102, no. 2, p. 111-122 (2019)
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid

The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against FVIII/FIX face an increased risk of bleeding, and the likelihood of early de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac48c3eca17d0c4b5c14c513b5933d0
http://hdl.handle.net/10486/692172

PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors

Autor: Guy Young, Victor S. Blanchette, Guenter Auerswald, Víctor Jiménez-Yuste, Massimo Morfini, Thierry Lambert, Elena Santagostino

Publikováno v: Thrombosis Research. 130:864-870

Introduction Hemophilia patients with inhibitors have frequent bleeding episodes and often develop hemophilic arthropathy which is in contradistinction to non-inhibitor patients for whom prophylaxis prevents joint disease. Recently, two prospective t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ddfeea2b8546905dd37e7863d44ff3
https://doi.org/10.1016/j.thromres.2012.08.305

Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery

Autor: James N. Huang, Guenter Auerswald, Carolyn M. Millar, Miguel A. Escobar, S. Austin, Miranda Norton

Introduction: Maintaining haemostasis in surgery is challenging for hereditary rare bleeding disorders in which multi-coagulation-factor concentrates are the only therapeutic option. Hereditary factor X (FX) deficiency affects 1:500 000 to 1:1 000 00

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a7eddc83f5638750d108ba2536d37ec
http://hdl.handle.net/10044/1/31004